As a result, EZH2 inhibitors represent a potential breakthrough strategy to enhance the efficacy of ICI-based immunotherapy by reshaping the characteristics of the tumor microenvironment towards a pro-immunogenic phenotype, [110]. Here, EZH2 is linked to neoplasm.